By Ahmed El-Medany
The 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure (HF) were published on the 27th of August.
New concepts include a new simplified treatment algorithm for heart failure with reduced ejection fraction (HFrEF), modified classification for acute heart failure, updated treatments for co-morbidities including diabetes, and updates on cardiomyopathies including the role of genetic testing and novel treatments.
The new guidelines focus on each phenotype of HF with regards to diagnosis and treatment. Notable new recommendations include the use of Dapagloflozin or Empagliflozin for HFrEF in reducing HF hospitilisation and death (Class I), and the use of Tafamidis in genetically proven hereditary transthyretin cardiac amyloidosis with NYHA class I or II symptoms (Class I).